South Korea
· Delayed Price · Currency is KRW Hwail Pharmaceutical Co.,Ltd. Statistics
Total Valuation
Hwail Pharmaceutical Co.,Ltd. has a market cap or net worth of KRW 112.43 billion.
| Market Cap | 112.43B |
| Enterprise Value | n/a |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
Hwail Pharmaceutical Co.,Ltd. has 75.36 million shares outstanding.
| Shares Outstanding | 75.36M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.01% |
| Owned by Institutions (%) | 4.23% |
| Float | 45.35M |
Valuation Ratios
The trailing PE ratio is 31.44.
| PE Ratio | 31.44 |
| Forward PE | n/a |
| PS Ratio | 0.56 |
| PB Ratio | 0.62 |
| P/FCF Ratio | 10.42 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.68, with a Debt / Equity ratio of 0.16.
| Current Ratio | 3.68 |
| Quick Ratio | 2.55 |
| Debt / Equity | 0.16 |
| Debt / EBITDA | 3.04 |
| Debt / FCF | 1.47 |
| Interest Coverage | 3.63 |
Financial Efficiency
Return on equity (ROE) is 1.94% and return on invested capital (ROIC) is 1.19%.
| Return on Equity (ROE) | 1.94% |
| Return on Assets (ROA) | 1.05% |
| Return on Capital (ROIC) | 1.19% |
| Revenue Per Employee | 829.81M |
| Profits Per Employee | 14.81M |
| Employee Count | 130 |
| Asset Turnover | 0.79 |
| Inventory Turnover | 3.46 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -26.50% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -26.50% |
| 50-Day Moving Average | 1,710.60 |
| 200-Day Moving Average | 1,709.88 |
| Relative Strength Index (RSI) | 37.36 |
| Average Volume (20 Days) | 1,376,870 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Hwail Pharmaceutical Co.,Ltd. had revenue of KRW 107.87 billion and earned 1.92 billion in profits. Earnings per share was 47.45.
| Revenue | 107.87B |
| Gross Profit | 14.09B |
| Operating Income | 2.28B |
| Pretax Income | 2.44B |
| Net Income | 1.92B |
| EBITDA | 5.20B |
| EBIT | 2.28B |
| Earnings Per Share (EPS) | 47.45 |
Balance Sheet
The company has 11.83 billion in cash and 15.83 billion in debt, giving a net cash position of -4.00 billion or -53.03 per share.
| Cash & Cash Equivalents | 11.83B |
| Total Debt | 15.83B |
| Net Cash | -4.00B |
| Net Cash Per Share | -53.03 |
| Equity (Book Value) | 98.03B |
| Book Value Per Share | 2,416.39 |
| Working Capital | 56.11B |
Cash Flow
In the last 12 months, operating cash flow was 11.20 billion and capital expenditures -417.08 million, giving a free cash flow of 10.79 billion.
| Operating Cash Flow | 11.20B |
| Capital Expenditures | -417.08M |
| Free Cash Flow | 10.79B |
| FCF Per Share | 143.13 |
Margins
Gross margin is 13.06%, with operating and profit margins of 2.12% and 1.78%.
| Gross Margin | 13.06% |
| Operating Margin | 2.12% |
| Pretax Margin | 2.26% |
| Profit Margin | 1.78% |
| EBITDA Margin | 4.82% |
| EBIT Margin | 2.12% |
| FCF Margin | 10.00% |
Dividends & Yields
Hwail Pharmaceutical Co.,Ltd. does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 105.38% |
| Buyback Yield | -0.15% |
| Shareholder Yield | -0.15% |
| Earnings Yield | 3.18% |
| FCF Yield | 9.59% |
Stock Splits
The last stock split was on March 17, 2021. It was a forward split with a ratio of 3.
| Last Split Date | Mar 17, 2021 |
| Split Type | Forward |
| Split Ratio | 3 |
Scores
Hwail Pharmaceutical Co.,Ltd. has an Altman Z-Score of 4.48.
| Altman Z-Score | 4.48 |
| Piotroski F-Score | n/a |